SciSparc Announces Additional Positive Results from Part 3 of Clearmind Medicine Inc. Preclinical Study for the Treatment of Cocaine Addiction
Results from preclinical in vivo research studies suggest that Clearmind’s MEAI drug candidate may be effective in treating addiction without disrupting the natural reward process. TEL AVIV, Israel, Jan. 17, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a clinical-stage specialty pharmaceutical company focused on developing therapies to treat central nervous system …